Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease
- PMID: 8849345
- DOI: 10.1002/art.1780381206
Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease
Abstract
Objective: To determine whether elevated soluble Fas/APO-1 (sFas/APO-1) levels are associated with either autoimmune disease or evidence of flares in autoimmune disease.
Methods: Thirty-seven serum samples were retrospectively obtained from normal controls and patients with laboratory evidence of autoimmune disease activity. These samples were assayed for sFas/APO-1 levels by an enzyme-linked immunosorbent assay, and hospital medical records were retrospectively reviewed for clinical and laboratory characteristics of the patients.
Results: Soluble Fas/APO-1 levels did not correlate with clinical diagnoses or laboratory abnormalities. The mean and range of sFas/APO-1 levels were similar in systemic lupus erythematosus patients (including those with active disease), patients with other autoimmune diseases, and normal controls.
Conclusion: These data strongly suggest that measurement of sFas/APO-1 levels is unlikely to hold clinical value or play a role in the pathogenesis of autoimmune disease.
Comment in
-
Use of sensitive assays to detect soluble Fas in patients with systemic lupus erythematosus: comment on the article by Knipping et al and the article by Goel et al.Arthritis Rheum. 1996 Sep;39(9):1611-2. doi: 10.1002/art.1780390925. Arthritis Rheum. 1996. PMID: 8814076 No abstract available.
Similar articles
-
Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.Clin Exp Immunol. 1997 Nov;110(2):303-9. doi: 10.1111/j.1365-2249.1997.tb08332.x. Clin Exp Immunol. 1997. PMID: 9367417 Free PMC article.
-
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.Arthritis Rheum. 1995 Dec;38(12):1735-7. doi: 10.1002/art.1780381205. Arthritis Rheum. 1995. PMID: 8849344
-
Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.Clin Exp Immunol. 1997 Jan;107(1):89-95. doi: 10.1046/j.1365-2249.1997.d01-901.x. Clin Exp Immunol. 1997. PMID: 9010262 Free PMC article.
-
Lupus in the Fas lane?J R Coll Physicians Lond. 1995 Nov-Dec;29(6):475-8. J R Coll Physicians Lond. 1995. PMID: 8748102 Free PMC article. Review.
-
CSF soluble Fas correlates with the severity of HIV-associated dementia.Neurology. 2004 Feb 24;62(4):654-6. doi: 10.1212/01.wnl.0000110188.37546.51. Neurology. 2004. PMID: 14981191 Review.
Cited by
-
Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives.Ann Rheum Dis. 2001 Mar;60(3):237-41. doi: 10.1136/ard.60.3.237. Ann Rheum Dis. 2001. PMID: 11171685 Free PMC article.
-
Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.J Clin Invest. 1996 Sep 1;98(5):1107-13. doi: 10.1172/JCI118892. J Clin Invest. 1996. PMID: 8787672 Free PMC article.
-
Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.J Clin Immunol. 2002 Jul;22(4):220-7. doi: 10.1023/a:1016040925295. J Clin Immunol. 2002. PMID: 12148596
-
Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.Clin Exp Immunol. 1997 Nov;110(2):303-9. doi: 10.1111/j.1365-2249.1997.tb08332.x. Clin Exp Immunol. 1997. PMID: 9367417 Free PMC article.
-
Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.Clin Rheumatol. 1998;17(6):496-9. doi: 10.1007/BF01451286. Clin Rheumatol. 1998. PMID: 9890678
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous